Vyepti (Eptinezumab-Jjmr) Patent Expiration, LOE Window & CMS Spending

Vyepti (Eptinezumab-Jjmr) by Lundbeck Seattle BioPharmaceuticals: Biologic BLA (Purple Book Regime), 0 AB generics, $34.7M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLundbeck Seattle BioPharmaceuticals
FDA Application & PathwayB761119 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$34.7M
2024 Medicare Part D Spend$15.1M
2024 Medicaid Spend$19.7M
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 21.0% 2-yr change)